EU 317349924 US 101525104

IN THE UNITED STATES PATENT AND TRADE MARK OFFICE 1 8 FEB 2005

Application of:

Edward J. Weinstein, et al.

Serial No:

TBA (§371 Application Based on PCT/US2003/025833)

Filed:

February 18, 2005

Title:

Antisense Modulation of Endothelial Specific Molecule 1 Expression

Group Art Unit:

TBA

Examiner:

TBA

Attorney Ref:

01189/3/US 27573/USA

Pfizer Ref:

27373703A

HDP Ref:

6794-000115/US/02

February 18, 2005

PRELIMINARY AMENDMENT A

Mail Stop PCT Commissioner For Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir/Madam:

The above-referenced patent application is a U.S. national phase application filed under 35 U.S.C. §371 based on International Patent Application No. PCT/US2003/025833 (filed August 19, 2003). Applicants request that this Preliminary Amendment A be entered into the above-referenced application.

Amendments to the specification begin on page 2.

Listing of claims (including amendments) begins on page 3.

Remarks begin on page 6.

Marked-up version of amendments to the specification begins on page 8.